Literature DB >> 20676043

ERBB3: Multifunctional enabler or primary actor in pancreatic cancer?

Ralf Landgraf1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20676043      PMCID： PMC3040945          DOI： 10.4161/cbt.10.6.12997

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


× No keyword cloud information.
  28 in total

1.  Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects.

Authors:  Paul Frohna; Jianfeng Lu; Steve Eppler; Marta Hamilton; Julie Wolf; Ashok Rakhit; Jie Ling; Saraswati R Kenkare-Mitra; Bert L Lum
Journal:  J Clin Pharmacol       Date:  2006-03       Impact factor: 3.126

2.  ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation.

Authors:  Fumin Shi; Shannon E Telesco; Yingting Liu; Ravi Radhakrishnan; Mark A Lemmon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

3.  An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.

Authors:  Xuewu Zhang; Jodi Gureasko; Kui Shen; Philip A Cole; John Kuriyan
Journal:  Cell       Date:  2006-06-16       Impact factor: 41.582

4.  Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.

Authors:  Natalia Jura; Yibing Shan; Xiaoxian Cao; David E Shaw; John Kuriyan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-09       Impact factor: 11.205

Review 5.  Pancreatic cancer--is the wall crumbling?

Authors:  Y J Chua; J R Zalcberg
Journal:  Ann Oncol       Date:  2008-04-01       Impact factor: 32.976

6.  Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.

Authors:  Gabriele Schaefer; Lihua Shao; Klara Totpal; Robert W Akita
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

7.  ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.

Authors:  Andrey Frolov; Kyle Schuller; Ching-Wei D Tzeng; Emily E Cannon; Brandon C Ku; J Harrison Howard; Selwyn M Vickers; Martin J Heslin; Donald J Buchsbaum; J Pablo Arnoletti
Journal:  Cancer Biol Ther       Date:  2007-04       Impact factor: 4.742

8.  MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Authors:  Jeffrey A Engelman; Kreshnik Zejnullahu; Tetsuya Mitsudomi; Youngchul Song; Courtney Hyland; Joon Oh Park; Neal Lindeman; Christopher-Michael Gale; Xiaojun Zhao; James Christensen; Takayuki Kosaka; Alison J Holmes; Andrew M Rogers; Federico Cappuzzo; Tony Mok; Charles Lee; Bruce E Johnson; Lewis C Cantley; Pasi A Jänne
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

9.  Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.

Authors:  Kenneth P Olive; Michael A Jacobetz; Christian J Davidson; Aarthi Gopinathan; Dominick McIntyre; Davina Honess; Basetti Madhu; Mae A Goldgraben; Meredith E Caldwell; David Allard; Kristopher K Frese; Gina Denicola; Christine Feig; Chelsea Combs; Stephen P Winter; Heather Ireland-Zecchini; Stefanie Reichelt; William J Howat; Alex Chang; Mousumi Dhara; Lifu Wang; Felix Rückert; Robert Grützmann; Christian Pilarsky; Kamel Izeradjene; Sunil R Hingorani; Pearl Huang; Susan E Davies; William Plunkett; Merrill Egorin; Ralph H Hruban; Nigel Whitebread; Karen McGovern; Julian Adams; Christine Iacobuzio-Donahue; John Griffiths; David A Tuveson
Journal:  Science       Date:  2009-05-21       Impact factor: 47.728

10.  Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.

Authors:  Natalia V Sergina; Megan Rausch; Donghui Wang; Jimmy Blair; Byron Hann; Kevan M Shokat; Mark M Moasser
Journal:  Nature       Date:  2007-01-07       Impact factor: 49.962
View more
  2 in total

1.  Anti-tumor efficacy of naked siRNAs for ERBB3 or AKT2 against lung adenocarcinoma cell xenografts.

Authors:  Gunamani Sithanandam; Laura W Fornwald; Janet R Fields; Nicole L Morris; Lucy M Anderson
Journal:  Int J Cancer       Date:  2011-05-28       Impact factor: 7.396

2.  HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models.

Authors:  Gaëlle Thomas; Thierry Chardès; Nadège Gaborit; Caroline Mollevi; Wilhem Leconet; Bruno Robert; Nina Radosevic-Robin; Frédérique Penault-Llorca; Céline Gongora; Pierre-Emmanuel Colombo; Yassamine Lazrek; Rui Bras-Goncalves; Ariel Savina; David Azria; Hervé Bazin; André Pèlegrin; Christel Larbouret
Journal:  Oncotarget       Date:  2014-08-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.